Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
Targets |
EC50: 79 nM (GPR35), 65 nM (ERK1/2)[1]
|
---|---|
ln Vitro |
Pamoic acid (0.1 nM-0.1 mM) stimulates GPR35a internalization with an EC50 value of 22 nM[1]. Pamoic acid (0-10 μM) promotes ERK1/2 activation [1].
|
ln Vivo |
In the abdominal contraction test, dose-related antinociceptive effects are induced by pamoic acid disodium (0-100 mg/kg; sc; once)[1].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: U2OS cells Tested Concentrations: 1, 10, 100 nM and 1, 10 μM Incubation Duration: 15 min Experimental Results: A concentration-dependent activation of ERK1/2 was observed with an EC50 of 65 nM. |
Animal Protocol |
Animal/Disease Models: Swiss-Webster mice (30–35 g)[1]
Doses: 25, 50, and 100 mg/kg Route of Administration: subcutaneous (sc) injection, once Experimental Results: Elicited dose-related antinociception, the dose causing 50% antinociception being 40.5 mg /kg. |
References |
[1]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8.
|
Molecular Formula |
C23H14NA2O6
|
---|---|
Molecular Weight |
432.33
|
CAS # |
6640-22-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
[Na+].[Na+].[O-]C1C(C(=O)O[H])=C([H])C2=C([H])C([H])=C([H])C([H])=C2C=1C([H])([H])C1=C(C(C(=O)O[H])=C([H])C2=C([H])C([H])=C([H])C([H])=C12)[O-]
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (231.30 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (17.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (17.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3130 mL | 11.5652 mL | 23.1305 mL | |
5 mM | 0.4626 mL | 2.3130 mL | 4.6261 mL | |
10 mM | 0.2313 mL | 1.1565 mL | 2.3130 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.